Genetic Testing for Cholesterol Drugs: A Customized Therapy

Genetic testing for cholesterol drugs can show whether your body is likely to handle a particular statin well or be more prone to muscle problems. This article covers the research background, then walks through the three genes in current statin guidelines, common side effects and how to use results with your prescriber.

Advances in the PGx Gene test bring a revolution to health care by tailoring medical treatments to individual genetic profiles. One area where the potential has seemed most promising is within the management of high cholesterol by using personalized drug therapy. Although statins remain the primary treatment for high cholesterol through lowering cholesterol, understanding the genetic testing for cholesterol drugs plays a significant role in effective treatment and minimizing adverse effects.

Why is genetic testing necessary for cholesterol drugs?

High lipid is one of the most critical risk factors for cardiovascular disease, significantly contributing to morbidity and mortality worldwide—some of the most prescribed lipid-lowering agents are Statin, Fibrates, niacin, and PCSK9 inhibitors. The treatment effect of these drugs is often heterogeneous across different patients; some experience muscle pain, while others rarely experience liver problems. Genetic testing for medications can identify individuals more likely to have an optimal response to these drugs and those who might need alternative treatment.

Critical Genes Involved in Statin Response

PGx Gene test of Rph Labs often involves genes related to metabolism, efficacy, and potential side effects of the drug. Among those studied more than others are:

• SLCO1B1: This gene expresses the protein responsible for transporting statins into the liver, where it acts to reduce cholesterol. At times, specific SLCO1B1 variants have been found to raise a risk of statin-induced myopathy (pain in muscles), especially at higher doses.
• CYP3A4 and CYP2C9: These genes fall in the cytochrome P450 family, which is significant for metabolizing statin drugs. Variants may also affect how quickly the individual’s body processes the drug, thus altering efficacy and increasing potential side effects.
• APOE: This gene has to do with lipid metabolism, and its variants affect LDL levels, although current guidelines do not use APOE to choose a statin.

Genes involved in PCSK9 Inhibitors

PCSK9 inhibitors, including alirocumab and evolocumab, lower LDL by binding to and blocking PCSK9 protein activity, thus changing lipid handling in the liver.

• PCSK9 Gene: Variants within the PCSK9 gene themselves can affect the levels of LDL at baseline and response to PCSK9 inhibitors. Individuals with PCSK9 loss-of-function mutations occurring naturally tend to have lower levels of LDL and usually benefit more from PCSK9 inhibitors.
• LDLR Gene: This gene encodes the LDLR, the receptors in liver cells to mop LDL out of blood circulation. PCSK9 inhibitors work by leaving more LDL receptors on liver cells, so they lower LDL less in people whose LDLR variants leave little or no working receptor.

Genes involved in Fibrates

Fibrates (such as fenofibrate and gemfibrozil) reduce triglycerides and increase HDL by activating peroxisome proliferator-activated receptor-alpha (PPAR-α).

• PPARA Gene: PPARA encodes the PPAR-α receptor. Variants of PPARA could significantly influence a patient’s response to fibrates since these medications act through PPAR-α activation to reduce triglyceride and increase HDL.
• APOA1 Gene: APOA1 is the major protein encoded by HDL and serves for lipid transport. Variants of APOA1 in genes can influence how fibrates impact the level of HDL among the patients.
• LPL (Lipoprotein Lipase) Gene: It activates triglyceride-rich lipoproteins degradation. Variations in LPL alter the triglyceride-lowering action of fibrates since this medicine works in a manner that depends on this enzyme.

Genes involved in Niacin (Vitamin B3)

Niacin or Vitamin B3 decreases cholesterol by VLDL and LDL cholesterol synthesis inhibition.

• HCAR2 (Hydroxycarboxylic Acid Receptor 2) Gene: This gene encodes the receptor to which niacin binds in lipid metabolism. Variants of this gene may affect the potency of niacin in reducing LDL and raising HDL.
• LIPC (Hepatic Lipase) Gene: This gene is associated with HDL metabolism and may account for some of the variation in the response of niacin on HDL elevation. The variants in this gene relate to different HDL responses in individuals treated with niacin.

PGx testing for the response of cholesterol drugs is relatively straightforward. Usually, it involves a cheek swab, blood sample, or sending a small amount of blood to the laboratory and contrasting it with the relevant genetic markers. The results then assist healthcare providers in determining each patient’s most influential and safest cholesterol-lowering strategy.

Advantages of PGx Genetic Testing in Cholesterol Management

• Personalized treatment: In the future, genetic tests could ascertain which patients would be good candidates for taking statins and which patients would require either a smaller dose or even alternative drugs.
• Reduced rate of adverse reactions: With the knowledge of the genetic tendency toward the adverse effect of statins such as myopathy, clinicians can make informed decisions. Increased-risk patients for side effects will benefit from alternative therapies like PCSK9 inhibitors or non-statin therapies.
• Improved Efficiency: Genetic direction helps physicians choose the proper medication and dosage to achieve maximum lipid reduction without having to guess and possibly make mistakes, thus proving both cost-effective and healthcare-directed.

The Future of Cholesterol Treatment and Genetic Testing

With lowering costs and growing awareness, more individualized lipid management can be expected. Advances in research are helping us understand the genetic basis of lipid metabolism further; this opens a venue for increasingly individualized care.

What genetic testing for cholesterol drugs checks today

Many genes have been studied in relation to cholesterol and lipid levels. Only a few, however, have strong enough evidence to guide prescribing decisions today. For statins, the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline focuses on three genes:

• SLCO1B1, which makes a transporter that moves statins from the blood into the liver. It applies to all statins.
• ABCG2, a transporter that affects blood levels of rosuvastatin.
• CYP2C9, a liver enzyme that breaks down fluvastatin.

The guidance is freely available on the CPIC guidelines site. It does not say whether you should take a statin. That decision is based on your heart risk. Instead, it helps your prescriber choose which statin and what dose, so you are more likely to stay on treatment comfortably.

Genes discussed elsewhere in this article, such as PCSK9, LDLR, PPARA or HCAR2, are important in research, but they are not currently used to choose between cholesterol drugs in routine care.

Common statin side effects to know about

Statins are among the most studied medicines in the world, and most people take them without trouble. Still, it helps to know which statin side effects are common and which are rare but serious.

More common

• Muscle aches, tenderness or weakness, often in the thighs, calves, shoulders or back
• Mild digestive upset, such as nausea or constipation
• Headache
• Small rises in liver enzymes on blood tests

Rare but serious

• Rhabdomyolysis, a severe breakdown of muscle that can damage the kidneys. Warning signs include severe muscle pain or weakness with dark, tea-colored urine.
• Significant liver injury, which can cause yellow skin or eyes, dark urine or pain in the upper right belly.

Statin side effects on this list are not the whole picture. Statin labels also note a small rise in blood sugar and HbA1c in some people. If you notice any serious warning sign, contact your prescriber or seek care promptly. For milder problems, keep taking your medicine and call your prescriber to talk it through.

The SLCO1B1 gene test and statin muscle pain

Of all the genes linked to statins, SLCO1B1 has the most evidence. When the SLCO1B1 transporter works less well, less of the statin is pulled into the liver. More stays in the bloodstream, where it can reach muscle tissue. That raises the risk of statin muscle pain and weakness, especially at higher doses.

The link is strongest for simvastatin. People with decreased or poor SLCO1B1 function have a clearly higher risk of myopathy on simvastatin, particularly at 80 mg, a dose the FDA already restricts for everyone. Guidelines suggest these patients consider a different statin or a lower dose.

An SLCO1B1 gene test reports your function as normal, decreased, possibly decreased, poor or increased. Most people have normal function. If your result shows decreased or poor function, it does not mean you cannot take a statin. It means your prescriber may choose the type and dose with extra care.

Our article on SLCO1B1 decreased function goes deeper into what each result means. MedlinePlus also has a clear summary of the SLCO1B1 gene.

Different statins, different genes

Statins are not all handled the same way, which is why a gene result can point toward one statin over another rather than ruling them all out.

• Simvastatin and lovastatin are strongly affected by SLCO1B1 and are broken down by CYP3A4. Drugs that block CYP3A4, such as clarithromycin, itraconazole and some HIV medicines, can raise their levels sharply. Grapefruit juice can have a similar effect.
• Atorvastatin is also broken down by CYP3A4 and is affected by SLCO1B1 to a moderate degree.
• Rosuvastatin is affected by SLCO1B1 and ABCG2. People with reduced ABCG2 function reach higher blood levels, so a lower starting dose may be suggested.
• Fluvastatin depends on CYP2C9 for breakdown, as well as SLCO1B1.
• Pravastatin and pitavastatin rely less on CYP enzymes but are still carried by SLCO1B1.

This is why genetic testing for cholesterol drugs is most helpful when read together with your full medication list. A gene result and a drug interaction can stack on top of each other and make statin side effects more likely. You can look up which medicines are linked to each gene on our medication list.

Statin intolerance: when genes are part of the story

Statin intolerance is the term doctors use when someone cannot keep taking a statin at a useful dose because of side effects, most often muscle symptoms. It is one of the main reasons people stop cholesterol treatment.

Genes are only one possible cause. Other factors that can raise the risk of muscle symptoms include:

• An underactive thyroid
• Kidney or liver disease
• Older age and low body weight
• Heavy or unaccustomed exercise
• Interacting medicines, including some antibiotics, antifungals and gemfibrozil
• Muscle aches from other causes that happen to begin after starting a statin

Because of this mix, your prescriber may check blood tests such as thyroid function or a muscle enzyme called creatine kinase. They may also suggest a short break followed by a different statin or a lower dose. An SLCO1B1 gene test adds useful context, especially after muscle symptoms on more than one statin.

A label of statin intolerance is not always permanent. Many people given that label can take a different statin, a lower dose or a less frequent schedule. Non-statin options also exist. Your prescriber can help find the right fit.

What to do about statin muscle pain

If you develop statin muscle pain, the first step is not to stop the medicine on your own. Statins protect against heart attack and stroke, and stopping abruptly without a plan can leave you unprotected.

1. Note where the pain is, when it started and whether it is getting worse.
2. Check for red flags: severe weakness, dark urine or fever. If present, seek care promptly.
3. Call your prescriber and describe what you are feeling. Mention any new medicines or supplements.
4. Ask whether blood tests, a dose change or a different statin make sense.
5. Ask whether an SLCO1B1 gene test could help guide the next choice.

Bring a list of every medicine you take, including over-the-counter products and supplements. Your pharmacist can also check for interactions that raise statin levels. Your pharmacist can also tell you whether any of your statin side effects might be caused by something else you take.

Keeping a simple symptom diary for a few weeks can be surprisingly helpful. Writing down the dose, the time you take it and how your muscles feel gives your prescriber real information to work with instead of a general impression.

Genetic testing for cholesterol drugs vs familial hypercholesterolemia testing

It is easy to mix up two very different kinds of genetic test. Pharmacogenomic testing looks at how your body handles medicines. It tells you nothing about whether you have inherited high cholesterol.

Familial hypercholesterolemia (FH) is an inherited condition, usually caused by a variant in LDLR, APOB or PCSK9, that leads to very high LDL from birth. Testing for FH is a diagnostic test ordered when someone has very high LDL, early heart disease or a strong family history. It can lead to earlier and more intensive treatment and testing of relatives.

The genes on a PGx panel, such as SLCO1B1, ABCG2 and CYP2C9, do not diagnose FH. If you have very high cholesterol or a family history of early heart attacks, ask your doctor whether FH testing is appropriate. That is a separate conversation from medication testing.

Who might benefit from testing and how to use results

Genetic testing for cholesterol drugs is not needed by everyone. You might consider it if you are about to start a statin, have had muscle problems on one before, need a high-intensity dose or take several interacting medicines. Results can also be reused for many other prescriptions in the future.

The RPh Labs at-home PGx test kit includes SLCO1B1, ABCG2, CYP2C9 and CYP3A4 among its 20 genes. You collect a cheek swab at home, mail it back with free shipping, and receive results 7 to 10 business days after the sample reaches the lab. Each report is reviewed by a PharmD pharmacist, and a free pharmacist consultation is included.

Once you have results, share them with the prescriber who manages your cholesterol. Together you can weigh your genes alongside your heart risk, other conditions and current medicines to choose the statin and dose most likely to work for you.

Conclusion

Cholesterol drugs represent an exciting frontier in personalized medicine: pharmacogenetic testing may lead to tailoring treatments according to the individual genetic makeup so that effectiveness in lowering cholesterol can be improved, the risk of side effects reduced, and the overall outcome bettered. Genetic testing may soon become routine in cholesterol management, ushering in a new era of personalized cardiovascular care.

Genetic testing for cholesterol drugs FAQ

Can a gene test tell me if I should take a statin?

No. Whether you need a statin depends on your cholesterol levels, heart risk, diabetes, age and other factors. A pharmacogenomic test helps your prescriber choose which statin and what dose are most likely to suit you once the decision to treat has been made.

Does a normal SLCO1B1 gene test mean I will not get muscle pain?

No. A normal result lowers one known source of risk, but muscle symptoms can still happen because of dose, drug interactions, thyroid problems, kidney disease, exercise or unrelated causes. Tell your prescriber about any new statin muscle pain whatever your gene result shows.

Which statin is least likely to cause statin muscle pain?

There is no single answer for everyone. For people with decreased SLCO1B1 function, guidelines suggest avoiding high-dose simvastatin and considering a lower dose or a statin less affected by that transporter. The best choice depends on your genes, other medicines and how much LDL lowering you need.

Is statin intolerance always genetic?

No. Genes such as SLCO1B1 are one contributor, but many cases involve drug interactions, thyroid problems, age, kidney disease or muscle aches from other causes. Your prescriber may check blood tests and try a different statin or dose before deciding what is going on. Talking openly about statin intolerance usually leads to a workable plan.

Will my insurance pay for a statin gene test?

Coverage varies by plan and by the reason for testing. RPh Labs accepts insurance including Medicare, Texas Medicaid and Blue Cross Blue Shield of Texas, and the self-pay price is $299 with HSA and FSA eligibility. The insurance page explains the options.